RELIEF THERAPEUTICS Holding AG announces today the completion of the business combination with Relief Therapeutics SA and the conversion of a CHF 3.3M convertible loan

18 July 2016

RELIEF THERAPEUTICS Holding AG (SIX: RLF, formerly TMX) (“RELIEF” or “the Company”) announces today that it has completed the business combination with Relief Therapeutics SA, changed its corporate name from THERAMetrics holding AG into RELIEF THERAPEUTICS Holding AG and transferred its corporate seat from Stans to Zurich.

The business combination was carried out by way of a dedicated ordinary capital increase in which the former shareholders of Relief Therapeutics SA contributed all their shares and were issued, in exchange, with 1’196’937’250 new shares of RELIEF.

Additionally, the Company also announces today that a CHF 3.3 million shareholder loan with all accrued interest has been mandatorily converted, with effect as of completion of the business combination with Relief Therapeutics SA, into shares of the Company. Thereby, 84’906’473 new shares of RELIEF have been issued out of conditional capital.

Starting 18 July 2016, all 1’936’627’375 RELIEF THERAPEUTICS Holding AG shares are listed and freely tradable under the ticker symbol RLF on the SIX Swiss Exchange under the International Reporting Standard.

Raffaele Petrone, CEO, states: “Today’s combination with Relief Therapeutics SA, marks the final step of THERAMetrics’ transformation from a contract research organization (CRO) to a drug development company. With a very lean corporate structure and a pipeline of promising drug candidates, several of which are already in advanced clinical development, together with a CHF 25 million financing facility from our largest shareholder, GEM Global Yield Fund, the company is now fully focused on advancing its pipeline to market and to achieving positive returns for our shareholders.”

Gaël Hédou, co-founder of Relief Therapeutics SA, states: “This transaction achieves the formation of a next-generation biotechnology company and unites Relief’s pipeline with that of the former THERAMetrics to create a diversified portfolio of drug candidates. We now look forward to starting the next set of clinical trials with our lead agents in the coming months.”

Chris Brown, Director and Founder of Global Emerging Markets (GEM), states: “This transaction, which GEM identified, structured and funded, gives Relief access to the public capital markets and thereby achieves a key step in Relief’s development. Relief’s combination with the former THERAMetrics facilitates the clinical development of Relief’s next-generation treatment for peripheral neuropathies and further advancement of the THERAMetrics clinical-stage pipeline, thus transformatively creating a new biotechnology company dedicated to therapeutic innovation to address unmet medical needs.”


RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins.  Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck-Serono, a division of the global established pharmaceutical firm Merck KGaA, and has been the subject of multiple clinical trials and over €100 million in total capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.

Investor relations contact:

Relief Therapeutics Holding AG
Dr. Raghuram Selvaraju
Tel: +41 44 723 59 59
This email address is being protected from spambots. You need JavaScript enabled to view it.


This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forwardlooking statements contained herein as a result of new information, future events or otherwise.